David H. Ingbar, MD

Chief Scientific Officer
Co-Founder

David Inbar, MD, is a nationally recognized physician-scientist and academic leader who serves as Chief Scientific Officer at Herald Therapeutics. Born and raised in Boston, MA, Dr. Ingbar earned a BA in Chemistry from Reed College in Portland, OR, and published his first research on thyroid disease in 1974. He went on to receive his MD from Harvard Medical School, followed by residency training and service as Chief Resident in Internal Medicine at the University of Washington. Dr. Ingbar completed a fellowship in Pulmonary and Critical Care Medicine at Yale University, where he later held faculty appointments as Assistant Professor of Medicine and Cell Biology.

Since joining the University of Minnesota in 1991, Dr. Ingbar has served as Professor of Medicine, Pediatrics, and Physiology. From 2001 to 2023, he led the Division of Pulmonary, Allergy, Critical Care and Sleep Medicine as Director, shaping its clinical, research, and educational missions. He also serves as Associate Director of the University of Minnesota Clinical and Translational Science Institute. A past President of the American Thoracic Society (ATS), Dr. Ingbar is a frequent NIH grant reviewer and has served on the NHLBI Council of Scientific Advisors since 2020.

With more than 225 publications, Dr. Ingbar has made landmark contributions to pulmonary and critical care medicine, including being the first in the world to administer human recombinant surfactant to a patient with ARDS, advancing translational science and improving care for patients with life-threatening lung disease.